Furthermore, HERIZON (IMU-ACS-001) is a clinical trial program that includes a phase Ib and a phase II clinical trial and aims to investigate the safety and efficacy of HER-vaxx for the treatment of G/GEJ cancer patients expressing HER-2 [50]. Here, ERBB2 is linked to cancer.